Overexpression and mutations of PSMB5 have been reported to contribute to drug resistance to proteasome inhibitors in several malignancies, such as multiple myeloma, breast cancer, and prostate cancer 66-68. The gene discussed is PSMB5; the disease is plasma cell myeloma.